BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15637733)

  • 1. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
    Cheng Y; Desreumaux P
    World J Gastroenterol; 2005 Jan; 11(3):309-14. PubMed ID: 15637733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
    Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid and chemoprevention: does it work?
    Lopez A; Peyrin-Biroulet L
    Dig Dis; 2013; 31(2):248-53. PubMed ID: 24030235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
    Herfarth H; Vavricka SR
    Inflamm Intest Dis; 2022 Jan; 7(1):28-35. PubMed ID: 35224015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
    Klotz U
    Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
    Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
    Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
    J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
    Ioffe AIu
    Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention for colon cancer: new opportunities, fact or fiction?
    Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
    Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bowel disease as a risk factor for colorectal cancer.
    Lukas M
    Dig Dis; 2010; 28(4-5):619-24. PubMed ID: 21088413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
    Dhaneshwar SS
    World J Gastroenterol; 2014 Apr; 20(13):3564-71. PubMed ID: 24707139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine.
    Lyakhovich A; Gasche C
    Aliment Pharmacol Ther; 2010 Jan; 31(2):202-9. PubMed ID: 19891667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Subramanian V; Logan RF
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):593-606. PubMed ID: 22122774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.